Abacavir (Ziagen)

Abacavir is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as abacavir slow down or prevent damage to the immune system and reduce the risk of developing AIDS-related illnesses.

Abacavir belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). When HIV infects a cell, the enzyme reverse transcriptase copies the viral single-stranded RNA genome into double-stranded viral DNA. This viral DNA is then integrated into the CD4 chromosomal DNA and can go on to reproduce in the body. Four natural nucleosides complete the DNA synthesis: adenosine, cytidine, guanosine, and thymidine. An NRTI drug substitutes a defective version of one of the nucleosides, causing premature termination of the proviral DNA chain.

In July 1999, abacavir was approved by the European Union licensing body for use in combination with other anti-HIV drugs. The drug was licensed in the United States in December 1998. Once-daily abacavir was also approved in the European Union in November 2004.

Abacavir was previously known by the codename 1592U89 and has been registered under the trade name Ziagen. It is made by GlaxoSmithKline, the company that also produces AZT (zidovudine, Retrovir) and 3TC (lamivudine, Epivir).

A pill that combines 300mg abacavir, 150mg 3TC and 300mg AZT called Trizivir, is also available from GlaxoSmithKline. It was approved in the United States in November 2000 and in the European Union in March 2001.

GlaxoSmithKline also produces a fixed-dose combination of 600mg abacavir with 300mg 3TC, which is suitable for once-daily dosing. It is marketed as Kivexa in the European Union, where it was licensed in December 2004. The same combination tablet is called Epzicom in the United States, where it was approved for use in August 2004.

Abacavir is recommended by WHO as an alternative NRTI in first-line therapy, either as part of an NRTI backbone for use with a non-nucleoside reverse transcriptase inhibitor or as part of a triple nucleoside regimen.1


  1. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, revised. World Health Organization, Geneva, available online at www.who.int.hiv/pub/guidelines/artadultguidelines.pdf [accessed 25 October 2008], 2006
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.